Literature DB >> 19249806

Neutralizing antibody responses to subtype B and C adjuvanted HIV envelope protein vaccination in rabbits.

Brian Burke1, Victor Raúl Gómez-Román, Ying Lian, Yide Sun, Elaine Kan, Jeffrey Ulmer, Indresh K Srivastava, Susan W Barnett.   

Abstract

Improving the potency, breadth, and durability of neutralizing antibody responses to HIV are major challenges for HIV vaccine development. To address these challenges, the studies described evaluate in rabbits the titers, breadth, and epitope specificities of antibody responses elicited by HIV envelope subunit vaccines adjuvanted with MF59 with or without CpG oligodeoxynucleotide (ODN). Animals were immunized with trimeric o-gp140DeltaV2 derived from subtype B HIV-1(SF162) or subtype C HIV-1(TV1), or proteins from both strains. Immunization with SF162 or TV1 with MF59/CpG elicited higher titers of binding and neutralizing antibodies to SF162 than monovalent immunization with MF59 alone (P<0.01). Bivalent immunization increased binding and neutralizing antibody titers over single envelope immunization in MF59 (P<0.01). Bivalent immunization also improved neutralization breadth. Epitope mapping indicated neutralizing activity in rabbits was directed to V3 and V4. Overall, our data suggests that a multivalent vaccination approach with MF59 and CpG can enhance humoral responses to HIV-1.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19249806      PMCID: PMC2705626          DOI: 10.1016/j.virol.2009.02.005

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  48 in total

1.  DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques.

Authors:  S Cherpelis; I Shrivastava; A Gettie; X Jin; D D Ho; S W Barnett; L Stamatatos
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Enhanced immune responses after DNA vaccination with combined envelope genes from different HIV-1 subtypes.

Authors:  Karl Ljungberg; Erik Rollman; Lars Eriksson; Jorma Hinkula; Britta Wahren
Journal:  Virology       Date:  2002-10-10       Impact factor: 3.616

3.  The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region.

Authors:  S W Barnett; S Lu; I Srivastava; S Cherpelis; A Gettie; J Blanchard; S Wang; I Mboudjeka; L Leung; Y Lian; A Fong; C Buckner; A Ly; S Hilt; J Ulmer; C T Wild; J R Mascola; L Stamatatos
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

4.  Structural characteristics correlate with immune responses induced by HIV envelope glycoprotein vaccines.

Authors:  Victoria A Sharma; Elaine Kan; Yide Sun; Ying Lian; Jimna Cisto; Verna Frasca; Susan Hilt; Leonidas Stamatatos; John J Donnelly; Jeffrey B Ulmer; Susan W Barnett; Indresh K Srivastava
Journal:  Virology       Date:  2006-08-15       Impact factor: 3.616

5.  Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis.

Authors:  M Dupuis; K Denis-Mize; A LaBarbara; W Peters; I F Charo; D M McDonald; G Ott
Journal:  Eur J Immunol       Date:  2001-10       Impact factor: 5.532

6.  Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells.

Authors:  Miren Kerkmann; Simon Rothenfusser; Veit Hornung; Andreas Towarowski; Moritz Wagner; Anja Sarris; Thomas Giese; Stefan Endres; Gunther Hartmann
Journal:  J Immunol       Date:  2003-05-01       Impact factor: 5.422

7.  Purification and characterization of oligomeric envelope glycoprotein from a primary R5 subtype B human immunodeficiency virus.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Harold Legg; Elaine Kan; Anne Fong; Stephen R Coates; Louisa Leung; Mark Wininger; John J Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2002-03       Impact factor: 5.103

8.  CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved.

Authors:  R Rankin; R Pontarollo; X Ioannou; A M Krieg; R Hecker; L A Babiuk; S van Drunen Littel-van den Hurk
Journal:  Antisense Nucleic Acid Drug Dev       Date:  2001-10

9.  Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate.

Authors:  Indresh K Srivastava; Leonidas Stamatatos; Elaine Kan; Michael Vajdy; Ying Lian; Susan Hilt; Loic Martin; Claudio Vita; Ping Zhu; Kenneth H Roux; Lucia Vojtech; David C Montefiori; John Donnelly; Jeffrey B Ulmer; Susan W Barnett
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  Synergistic adjuvant activity of immunostimulatory DNA and oil/water emulsions for immunization with HIV p55 gag antigen.

Authors:  D T O'Hagan; M Singh; J Kazzaz; M Ugozzoli; M Briones; J Donnelly; G Ott
Journal:  Vaccine       Date:  2002-09-10       Impact factor: 3.641

View more
  18 in total

1.  Conserved structural elements in the V3 crown of HIV-1 gp120.

Authors:  Xunqing Jiang; Valicia Burke; Maxim Totrov; Constance Williams; Timothy Cardozo; Miroslaw K Gorny; Susan Zolla-Pazner; Xiang-Peng Kong
Journal:  Nat Struct Mol Biol       Date:  2010-07-11       Impact factor: 15.369

Review 2.  Role of adjuvants in modeling the immune response.

Authors:  Darrick Carter; Steven G Reed
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

3.  An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120.

Authors:  Adi Moseri; Subramanyam Tantry; Yael Sagi; Boris Arshava; Fred Naider; Jacob Anglister
Journal:  Virology       Date:  2010-03-26       Impact factor: 3.616

4.  A multivalent clade C HIV-1 Env trimer cocktail elicits a higher magnitude of neutralizing antibodies than any individual component.

Authors:  Christine A Bricault; James M Kovacs; Joseph P Nkolola; Karina Yusim; Elena E Giorgi; Jennifer L Shields; James Perry; Christy L Lavine; Ann Cheung; Katharine Ellingson-Strouss; Cecelia Rademeyer; Glenda E Gray; Carolyn Williamson; Leonidas Stamatatos; Michael S Seaman; Bette T Korber; Bing Chen; Dan H Barouch
Journal:  J Virol       Date:  2014-12-24       Impact factor: 5.103

5.  Use of a polyanionic carbomer, Carbopol971P, in combination with MF59, improves antibody responses to HIV-1 envelope glycoprotein.

Authors:  Antu K Dey; Brian Burke; Yide Sun; Karin Hartog; Jonathan L Heeney; David Montefiori; Indresh K Srivastava; Susan W Barnett
Journal:  Vaccine       Date:  2012-02-22       Impact factor: 3.641

6.  Preparation, characterization and immunogenicity of HIV-1 related high-mannose oligosaccharides-CRM197 glycoconjugates.

Authors:  Anna Kabanova; Roberto Adamo; Daniela Proietti; Francesco Berti; Marta Tontini; Rino Rappuoli; Paolo Costantino
Journal:  Glycoconj J       Date:  2010-06-04       Impact factor: 2.916

Review 7.  Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design.

Authors:  Susan Zolla-Pazner; Timothy Cardozo
Journal:  Nat Rev Immunol       Date:  2010-07       Impact factor: 53.106

8.  Functional and Structural Characterization of Human V3-Specific Monoclonal Antibody 2424 with Neutralizing Activity against HIV-1 JRFL.

Authors:  Rajnish Kumar; Ruimin Pan; Chitra Upadhyay; Luzia Mayr; Sandra Cohen; Xiao-Hong Wang; Preetha Balasubramanian; Arthur Nádas; Michael S Seaman; Susan Zolla-Pazner; Miroslaw K Gorny; Xiang-Peng Kong; Catarina E Hioe
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

9.  Breadth of neutralizing antibodies elicited by stable, homogeneous clade A and clade C HIV-1 gp140 envelope trimers in guinea pigs.

Authors:  Joseph P Nkolola; Hanqin Peng; Ethan C Settembre; Michael Freeman; Lauren E Grandpre; Colleen Devoy; Diana M Lynch; Annalena La Porte; Nathaniel L Simmons; Ritu Bradley; David C Montefiori; Michael S Seaman; Bing Chen; Dan H Barouch
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

10.  HIV-1 variable loop 2 and its importance in HIV-1 infection and vaccine development.

Authors:  Mangala Rao; Kristina K Peachman; Jiae Kim; Guofen Gao; Carl R Alving; Nelson L Michael; Venigalla B Rao
Journal:  Curr HIV Res       Date:  2013-07       Impact factor: 1.581

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.